AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUN 27 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Medical investigators have now discerned how PTEN gene expression might sensitize ovarian cancer cells to a metabolite of the chemotherapy irinotecan, which is a topoisomerase I inhibitor.
"PTEN is a tumor suppressor gene that was identified on chromosome 10q23. In addition to its original function as a tumor suppressor, this gene product was recently reported to enhance the sensitivity of cancer cells to anticancer agents," described Yasushi Saga and coauthors, Jichi Medical School, Tochigi, Japan, in the journal Clinical Cancer Research.
By introducing cDNA from this gene into an ovarian cancer cell line (SHIN-3), Saga and colleagues have been able to track how it sensitizes cells to SN-38, a metabolite of irinotecan.
"In vitro examination of sensitivity to anticancer agents showed that the 50% growth-inhibitory concentration value for SN-38 in SHIN-3/PTEN was 800 nM, a 6.6-fold sensitivity compared with that of the control (5300 nM)," reported Saga and associates.
The sensitivity of SHIN-3 cells to other chemotherapies, including cisplatin, paclitaxel, or gemcitabine, was not enhanced by PTEN, according to the researchers.
Average apoptosis in SN-38 treated cells after 1 day was almost double that ...
Source: HighBeam Research, PTEN tumor suppressor gene enhances cellular response to cancer...